Michael Yee

“One was just thinking about the first year of the launch. I know there will be focus on sales and the success metrics of the launch.”

“We wanted to ask about your expectations for the prep launch and assuming approval on time, how you think about the dynamics in the second half related to commercial reimbursement and Medicaid reimbursement, and whether guideline changes and other factors also need to play a role.”

“Looking ahead to the approval of LEN for PrEP, can you just comment about your recent interactions with the FDA and the perspective of the FDA and HHS with the incoming administration with the U.S. and that there should be no issues with a fast approval?”

“Following up on the Tridelvy data coming at ASCO and your enthusiasm for frontline, can you just remind us, A, do you believe that your data in evoke second line that will be ASCO is at least as competitive or better than Astra, and that is why you're excited about Frontline.”

“There were some comments around the dynamics of the channel mix as it relates to HIV pricing. And I was wondering if you could just remind us about what the driver of the benefit was in 2022 and 2023 and how that changed as we go into 2024 and why that's difficult comps.”